title: Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.
abstract: Abnormal DNA methylation is a feature of most types of cancer, which is reflected in cell-free circulating DNA in plasma. It is, however, unknown whether surgical removal of the tumor and subsequent therapy induces changes in plasma DNA methylation, which can be used to monitor treatment. In this pilot study, methylation in cell-free plasma DNA of 20 breast cancer patients was determined by the previously developed MethDet-56 technique. Samples at three time points were analyzed-before surgery (baseline), after surgery (to evaluate the effects of resection) and after surgery on tamoxifen therapy (to determine the effects of treatment). Methylation patterns of healthy controls were used as a reference for all comparisons. Seven promoters were differentially methylated (p < 0.05) in at least one comparison; three changed after surgery; another one changed after beginning of tamoxifen treatment; and four were differentially methylated in baseline versus combined treatment samples. Increased methylation of PR PROX, MDGI, PAX 5 and RARβ2 at baseline (presurgery) diminished toward the healthy controls with the lowest methylation in the combined treatment group. Surgery alone decreased methylation in PAX 5 and RARβ2, whereas tamoxifen treatment changed methylation only in the B promoter of ESR1. Methylation patterns in cell-free plasma DNA change after surgery and tamoxifen treatment, most significantly-after combined treatment. The baseline (presurgery) patterns become similar to those of healthy controls, suggesting that methylation patterns in cell-free plasma DNA may be used to monitor treatment.
authors.affiliation: Department of Neurology, Rush University Medical Center, Chicago, IL, USA.
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Liggett
authors.forename: Anatoliy A
authors.initials: AA
authors.lastname: Melnikov
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Marks
authors.forename: Victor V
authors.initials: VV
authors.lastname: Levenson
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000235:genetics*; D011401:Promoter Regions, Genetic; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D004273:DNA, Neoplasm; D013629:Tamoxifen
references.citation: Br J Haematol. 1994 Apr;86(4):774-9
references.pmid: 7918071
references.citation: J Mol Diagn. 2008 Jan;10(1):93-101
references.pmid: 18165279
references.citation: Clin Cancer Res. 2009 Feb 15;15(4):1184-91
references.pmid: 19228724
references.citation: Endocrine. 2000 Aug;13(1):1-10
references.pmid: 11051041
references.citation: Cancer Res. 1996 Nov 1;56(21):4865-70
references.pmid: 8895735
references.citation: Ann Oncol. 2000 Sep;11(9):1097-104
references.pmid: 11061602
references.citation: J Cell Sci. 2008 Oct 1;121(Pt 19):3146-54
references.pmid: 18765568
references.citation: Br J Cancer. 1997;76(10):1293-9
references.pmid: 9374374
references.citation: J Mol Diagn. 2009 Jan;11(1):60-65
references.pmid: 19074590
references.citation: Int J Cancer. 2003 Jun 20;105(3):361-70
references.pmid: 12704670
references.citation: Br J Cancer. 2009 Apr 21;100(8):1277-86
references.pmid: 19367284
references.citation: Ann N Y Acad Sci. 2001 Dec;949:72-9
references.pmid: 11795383
references.citation: Gastroenterology. 1997 Apr;112(4):1114-20
references.pmid: 9097993
references.citation: Mol Oncol. 2008 Jun;2(1):33-40
references.pmid: 19383327
references.citation: Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R50-9
references.pmid: 17613547
references.citation: J Surg Oncol. 2009 Feb 1;99(2):119-22
references.pmid: 19065635
references.citation: Mod Pathol. 2007 Jul;20(7):711-21
references.pmid: 17464311
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Cancer Biol Ther. 2008 Jun;7(6):958-65
references.pmid: 18379196
references.citation: Gynecol Oncol. 2004 May;93(2):435-40
references.pmid: 15099958
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8152-62
references.pmid: 15623589
references.citation: Ann N Y Acad Sci. 2004 Jun;1022:44-9
references.pmid: 15251938
references.citation: Carcinogenesis. 2000 Dec;21(12):2193-201
references.pmid: 11133808
references.citation: Ann N Y Acad Sci. 2000 Apr;906:25-8
references.pmid: 10818591
references.citation: Clin Cancer Res. 1998 Feb;4(2):271-5
references.pmid: 9516910
references.citation: Oncogene. 2000 Mar 16;19(12):1556-63
references.pmid: 10734315
references.citation: Br J Cancer. 2006 May 22;94(10):1492-5
references.pmid: 16641902
references.citation: Cancer Res. 2001 Apr 1;61(7):3105-9
references.pmid: 11306494
references.citation: Nat Med. 1996 Sep;2(9):1033-5
references.pmid: 8782463
references.citation: Ann N Y Acad Sci. 2000 Apr;906:5-7
references.pmid: 10818586
references.citation: Genes Chromosomes Cancer. 1999 Feb;24(2):160-1
references.pmid: 9885984
references.citation: Cancer Res. 2003 Mar 1;63(5):1114-21
references.pmid: 12615730
references.citation: Ann Oncol. 1998 Jan;9(1):113-6
references.pmid: 9541693
references.citation: Int J Cancer. 2003 Jan 10;103(2):149-52
references.pmid: 12455027
references.citation: Cancer Res. 1999 Jan 1;59(1):67-70
references.pmid: 9892187
references.citation: Cancer. 2010 Apr 1;116(7):1674-80
references.pmid: 20143430
references.citation: J Neurol Sci. 2010 Mar 15;290(1-2):16-21
references.pmid: 20064646
references.citation: Cancer Res. 2003 Aug 1;63(15):4620-5
references.pmid: 12907641
references.citation: Br J Cancer. 1999 Jun;80(8):1262-4
references.pmid: 10376981
references.citation: Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):67-71
references.pmid: 8118388
references.citation: J Clin Oncol. 2000 Sep;18(17):3172-86
references.pmid: 10963646
references.citation: Mol Endocrinol. 2001 Dec;15(12):2057-63
references.pmid: 11731608
references.citation: Oncogene. 2002 Aug 12;21(35):5462-82
references.pmid: 12154408
references.citation: Ann Surg Oncol. 2002 Jan-Feb;9(1):71-6
references.pmid: 11829433
references.citation: Cancer Res. 2002 Jan 15;62(2):371-5
references.pmid: 11809682
references.citation: Cancer Res. 1994 May 15;54(10):2552-5
references.pmid: 8168078
references.citation: Nucleic Acids Res. 2005 Jun 08;33(10):e93
references.pmid: 15944447
references.citation: Adv Cancer Res. 1998;72:141-96
references.pmid: 9338076
references.citation: Cancer Res. 1998 Jun 15;58(12):2515-9
references.pmid: 9635570
references.citation: Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93
references.pmid: 15448006
references.citation: Ann N Y Acad Sci. 2004 Jun;1022:17-24
references.pmid: 15251934
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3036-43
references.pmid: 19861523
references.citation: Cancer Res. 2005 Feb 15;65(4):1141-5
references.pmid: 15734995
references.citation: Semin Oncol. 2001 Jun;28(3):260-73
references.pmid: 11402436
references.citation: Clin Cancer Res. 1996 May;2(5):805-10
references.pmid: 9816234
references.citation: Ann N Y Acad Sci. 2000 Apr;906:72-82
references.pmid: 10818600
references.citation: J Mol Med (Berl). 2005 Feb;83(2):132-9
references.pmid: 15536519
references.citation: J Clin Oncol. 2006 Sep 10;24(26):4262-9
references.pmid: 16908936
references.citation: Lancet. 1998 Sep 19;352(9132):930-42
references.pmid: 9752815